Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2013 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that azilsartan medoxomil/chlorthalidone (AZL-M/CLD) not be listed. Indexing Status Subject indexing assigned by CRD MeSH Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Oxadiazoles Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000873 Date abstract record published 17/07/2014 |